McNeilage L J, Macmillan E M, Whittingham S F
Burnet Clinical Research Unit, Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, Victoria, Australia.
J Immunol. 1990 Dec 1;145(11):3829-35.
Autoepitopes on the ribonucleoprotein La(SS-B) were identified by using recombinant La(SS-B) polypeptides and sera from 166 patients with the antinuclear autoantibody anti-La(SS-B). The La(SS-B) polypeptides were encoded by polymerase chain reaction-derived overlapping or nonoverlapping fragments of the La(SS-B) gene, which encodes a protein of 408 amino acids (aa). Of the 166 sera tested, 99% reacted with a fusion protein comprising the first 107 N-terminal aa (LaA); 91% reacted with a fusion protein comprising aa 111 to 242 (LaC), and 91% reacted with a fusion protein comprising aa 346 to 408 (LaL2/3) at the C terminus of La(SS-B). The order of immunodominance as assessed by the number of sera reacting with each epitope and the strength of the reactivity was LaA (aa 1 to 107) greater than LaC (aa) 111 to 242) much greater than LaL2/3 (aa 346 to 408). Cross-reactivity was observed between antibodies eluted from LaC (aa 111 to 242) and LaL2/3 (aa 346 to 408), but there was no significant primary sequence homology between the two regions. The LaC region contained at least two epitopes, one encompassing a putative RNA-binding motif (aa 112 to 187) which was recognized by 83% of patient sera. Serial serum samples from three patients showed that the antibody response to La(SS-B) was initially directed to the N terminus (LaA, aa 1 to 107), but over a period of time all three major epitopes, including that encompassing the putative RNA-binding motif, were recognized. This result suggests that the primary immune response to La(SS-B) is restricted to an immunodominant epitope. As the specificity of the autoantibody response broadens, it includes the RNA-binding motif, which may have important implications for the expression of disease.
通过使用重组La(SS - B)多肽以及来自166名抗核自身抗体抗La(SS - B)患者的血清,确定了核糖核蛋白La(SS - B)上的自身表位。La(SS - B)多肽由聚合酶链反应衍生的La(SS - B)基因的重叠或非重叠片段编码,该基因编码一种含408个氨基酸(aa)的蛋白质。在检测的166份血清中,99%与包含前107个N端氨基酸(LaA)的融合蛋白发生反应;91%与包含第111至242位氨基酸(LaC)的融合蛋白发生反应,91%与包含La(SS - B) C端第346至408位氨基酸(LaL2/3)的融合蛋白发生反应。根据与每个表位反应的血清数量和反应强度评估的免疫显性顺序为:LaA(第1至107位氨基酸)大于LaC(第111至242位氨基酸),远大于LaL2/3(第346至408位氨基酸)。在从LaC(第111至242位氨基酸)和LaL2/3(第346至408位氨基酸)洗脱的抗体之间观察到交叉反应,但这两个区域之间没有明显的一级序列同源性。LaC区域包含至少两个表位,其中一个包含一个假定的RNA结合基序(第112至187位氨基酸),83%的患者血清可识别该基序。来自三名患者的系列血清样本显示,对La(SS - B)的抗体反应最初针对N端(LaA,第1至107位氨基酸),但一段时间后,所有三个主要表位,包括包含假定RNA结合基序的表位,都被识别。这一结果表明,对La(SS - B)的初始免疫反应局限于一个免疫显性表位。随着自身抗体反应特异性的扩大,它包括RNA结合基序,这可能对疾病的表达具有重要意义。